Cycle control and bleeding pattern of a 24/4 regimen of drospirenone 3μg/ethinylestradiol 20μg compared with a 21/7 regimen of desogestrel 150μg/ethinylestradiol 20μg: A pooled analysis

Clinical Drug Investigation

Volumn 31, Issue 8, 2011, Pages 519-525

  Anttila, Leena ^a,e   Neunteufel, Walter ^b   Petraglia, Felice ^c   Marr, Joachim ^d   Kunz, Michael ^d  

^a Family Federation of Finland   (Finland)

^b General Hospital Dornbirn   (Austria)

^c UNIVERSITY OF SIENA   (Italy)

^d BAYER PHARMA AG   (Germany)

^e Head of the Clinic   (Finland)

Author keywords

Combined oral contraceptives; Ethinylestradioldesogestrel; Ethinylestradioldrospirenone.

Indexed keywords

DESOGESTREL PLUS ETHINYLESTRADIOL; DROSPIRENONE PLUS ETHINYLESTRADIOL;

ARTICLE; BLEEDING; FEMALE; HUMAN; INTRACYCLIC BLEEDING; LOW DRUG DOSE; MENSTRUAL CYCLE; MENSTRUATION; META ANALYSIS; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPOTTING; SYSTEMATIC REVIEW; VAGINA BLEEDING; WITHDRAWAL BLEEDING;

ADOLESCENT; ADULT; ANDROSTENES; CONTRACEPTIVES, ORAL; CONTRACEPTIVES, ORAL, COMBINED; DESOGESTREL; ETHINYL ESTRADIOL; FEMALE; HUMANS; MENSTRUAL CYCLE; MENSTRUATION; METRORRHAGIA; YOUNG ADULT;

EID: 79959944387     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11590260-000000000-00000     Document Type: Article

References (27)

1. Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1998; 179: 577-82 (Pubitemid 28447229)
2. RosenbergMJ, Long SC. Oral contraceptives and cycle control: a critical review of the literature.Adv Contracept 1992; 8: 35-45
3. Thorneycroft H, Gollnick H, Schellschmidt I. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment. Cutis 2004; 74: 123-30 (Pubitemid 39207746)
4. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000; 62: 29-38
5. Foidart JM, Wuttke W, Bouw GM, et al. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 2000; 5: 124-34 (Pubitemid 30470064)
6. Huber J, Foidart JM, Wuttke W, et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care 2000; 5: 25-34 (Pubitemid 30321317)
7. Bachmann G, Sulak PJ, Sampson-Landers C, et al. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3mg drospirenone. Contraception 2004; 70: 191-8 (Pubitemid 39119980)
8. Koltun W, Lucky AW, Thiboutot D, et al. Efficacy and safety of 3mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebocontrolled trial. Contraception 2008; 77: 249-56
9. Lucky AW, KoltunW, Thiboutot D, et al. A combined oral contraceptive containing 3-mg drospirenone/20-microg ethinyl estradiol in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment. Cutis 2008; 82: 143-50
10. Maloney JM, Dietze P, Watson D, et al. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial. Obstet Gynecol 2008; 112: 773-81
11. Pearlstein TB, Bachmann GA, Zacur HA, et al. Treatment of premenstrual dysphoric disorder with a new drospirenonecontaining oral contraceptive formulation. Contraception 2005; 72: 414-21 (Pubitemid 41676830)
12. Yonkers KA, Brown C, Pearlstein TB, et al. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 2005; 106: 492-501 (Pubitemid 41208780)
13. Anttila L, Kunz M, Marr J. Bleeding pattern with drospirenone 3mg + ethinylestradiol 20mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg + ethinylestradiol 20mcg 21/7 combined oral contraceptive. Contraception 2009; 80: 445-51
14. Gruber DM, Huber JC, Melis GB, et al. A comparison of the cycle control, safety, and efficacy profile of a 21-day regimen of ethinylestradiol 20mcg and drospirenone 3mg with a 21-day regimen of ethinylestradiol 20 mcg and desogestrel 150 mcg. Treat Endocrinol 2006; 5: 115-21
15. Klipping C, Marr J. Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. Contraception 2005; 71: 409-16 (Pubitemid 40725775)
16. Belsey EM, Machin D, dArcangues C. The analysis of vaginal bleeding patterns induced by fertility regulating methods. World Health Organization Special Programme of Research, Development and Research Training in Human Reproduction. Contraception 1986; 34: 253-60
17. Kirkman RJ, Pederse JH, Fioretti P, et al. Clinical comparison of two low-dose oral contraceptives, Minulet and Mercilon, in women over 30 years of age. Contraception 1994; 49: 33-46 (Pubitemid 24077386)
18. Lammers P, op ten Berg M: Phase III clinical trial with a new oral contraceptive containing 150 micrograms desogestrel and 20 micrograms ethinylestradiol. Acta Obstet Gynecol Scand 1991; 70: 497-500
19. Endrikat J, Cronin M, Gerlinger C, et al. Open, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day oral contraceptive regimen with 20 microg ethinyl estradiol and 75 microg gestodene and a 21-day regimen with 20 microg ethinyl estradiol and 150 microg desogestrel. Contraception 2001; 64: 201-7 (Pubitemid 33042591)
20. Endrikat J, Cronin M, Gerlinger C, et al. Double-blind, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day versus a 21-day low-dose oral contraceptive regimen containing 20 microg ethinyl estradiol and 75 microg gestodene. Contraception 2001; 64: 99-105 (Pubitemid 33042596)
21. Kaunitz AM, Burkman RT, Fisher AC, et al. Cycle control with a 21-day compared with a 24-day oral contraceptive pill: a randomized controlled trial. Obstet Gynecol 2009; 114: 1205-12
22. Mishell Jr DR, Guillebaud J, Westhoff C, et al. Combined hormonal contraceptive trials: variable data collection and bleeding assessment methodologies influence study outcomes and physician perception. Contraception 2007; 75: 4-10 (Pubitemid 44854862)
23. Archer DF, Maheux R, DelConte A, et al. A new lowdose monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 micrograms and ethinyl estradiol 20 micrograms. North American Levonorgestrel Study Group (NALSG). Contraception 1997; 55: 139-44 (Pubitemid 27180388)
24. Archer DF, Maheux R, DelConte A, et al. Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 microg levonorgestrel and 20 microg ethinyl estradiol (Alesse). North American Levonorgestrel Study Group (NALSG). Am J Obstet Gynecol 1999; 181: 39-44
25. Parsey KS, Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception 2000; 61: 105-11 (Pubitemid 30236331)
26. Spona J, Elstein M, Feichtinger W, et al. Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception 1996; 54: 71-7 (Pubitemid 26256707)
27. Sullivan H, Furniss H, Spona J, et al. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity. Fertil Steril 1999; 72: 115-20 (Pubitemid 29300271)